Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $457000.0.

  • Evogene's Accounts Payables fell 6185.31% to $457000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $457000.0, marking a year-over-year decrease of 6185.31%. This contributed to the annual value of $1.2 million for FY2024, which is 3120.45% down from last year.
  • Latest data reveals that Evogene reported Accounts Payables of $457000.0 as of Q3 2025, which was down 6185.31% from $557000.0 recorded in Q2 2025.
  • Over the past 5 years, Evogene's Accounts Payables peaked at $1.8 million during Q3 2021, and registered a low of $457000.0 during Q3 2025.
  • For the 5-year period, Evogene's Accounts Payables averaged around $1.1 million, with its median value being $1.2 million (2023).
  • In the last 5 years, Evogene's Accounts Payables soared by 16390.87% in 2021 and then plummeted by 6185.31% in 2025.
  • Evogene's Accounts Payables (Quarter) stood at $1.5 million in 2021, then decreased by 29.19% to $1.0 million in 2022, then surged by 72.3% to $1.8 million in 2023, then crashed by 31.2% to $1.2 million in 2024, then plummeted by 62.79% to $457000.0 in 2025.
  • Its Accounts Payables was $457000.0 in Q3 2025, compared to $557000.0 in Q2 2025 and $592000.0 in Q1 2025.